News | Cardiovascular Ultrasound | April 29, 2022

Study Evaluates AI Software that Aids Novice Users Performing Echocardiogram

Aurora St. Luke’s Medical Center in Milwaukee is the first site in the country to participate in the clinical trial.

Aurora St. Luke’s Medical Center in Milwaukee is the first site in the country to join a clinical trial studying machine-learning software designed to help novice users perform an echocardiography exam.

The study will evaluate the UltraSight Echocardiographic Guidance software.


April 29, 2022 – Aurora St. Luke’s Medical Center in Milwaukee is the first site in the country to join a clinical trial studying machine-learning software designed to help novice users perform an echocardiography exam.

“Echocardiography, or an ultrasound of the heart, is the most widely used imaging method in cardiology,” said Bijoy Khandheria, MD, Advocate Aurora Research Institute’s principal investigator for the study. “It is more portable, less expensive and has fewer side effects than other cardiac imaging technologies. However, echocardiography requires intensive training in order to obtain accurate results.”

The clinical trial evaluates the safety and efficacy of UltraSight Echocardiographic Guidance (USEG) software. The software is a machine-learning, downloadable mobile application that uses artificial intelligence to provide real-time guidance on how to position the transducer, or wand-like device used to obtain the ultrasound images, when performing an echocardiogram. It is designed to help medical professionals who do not have advanced training in echocardiography obtain diagnostic-quality images of the heart.

“Echocardiography is useful for diagnosing a wide range of cardiac conditions, and the ultrasound images it produces can be evaluated in real time, making it valuable in a variety of settings, from outpatient clinics to emergency departments,” said Laura Wrona, MSN, director of cardiovascular clinical trials research. “By guiding novice users – perhaps a medical resident, nurse practitioner or physician assistant – through a limited exam, the USEG software has the potential to help health care providers more quickly detect urgent findings regarding the heart’s function.”

Participants will be asked to join the study because they have a cardiac echocardiogram scheduled as part of their standard medical care. If they consent to join the study, each participant will first undergo their scheduled standard of care echocardiogram. Then, as part of the research study, an expert sonographer will conduct an echocardiogram without assistance from the USEG software followed by a novice user who will receive guidance from the USEG software. Researchers will then assess the quality of the images obtained.

The study will evaluate the USEG software, not the device used to perform the echocardiogram. The transducer used to obtain the ultrasound images in this study is already approved by the U.S. Food and Drug Administration for commercial use. The USEG software is designed to work with any transducer.

The clinical trial, “Study for the assessment of the quality of echocardiographic clips,” is sponsored by UltraSight, developer of the USEG software.

To learn more about Advocate Aurora’s research, visit aah.org/research.

Related Content

News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Subscribe Now